4.7 Article

Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia

期刊

LEUKEMIA
卷 34, 期 9, 页码 2342-2353

出版社

SPRINGERNATURE
DOI: 10.1038/s41375-020-0764-6

关键词

-

资金

  1. National Cancer Institute [1R01CA183947, 1U01CA217862, 1U54CA224019, 3P30CA069533]
  2. V Foundation for Cancer Research
  3. Gabrielle's Angel Foundation for Cancer Research
  4. Agios
  5. Aptose
  6. Array
  7. AstraZeneca
  8. Constellation
  9. Genentech
  10. Gilead
  11. Incyte
  12. Janssen
  13. Petra
  14. Seattle Genetics
  15. Syros
  16. Takeda

向作者/读者索取更多资源

Acute myeloid leukemia (AML) results from the enhanced proliferation and impaired differentiation of hematopoietic stem and progenitor cells. Using an ex vivo functional screening assay, we identified that the combination of the BTK inhibitor ibrutinib and BCL2 inhibitor venetoclax (IBR + VEN), currently in clinical trials for chronic lymphocytic leukemia (CLL), demonstrated enhanced efficacy on primary AML patient specimens, AML cell lines, and in a mouse xenograft model of AML. Expanded analyses among a large cohort of hematologic malignancies (n = 651 patients) revealed that IBR + VEN sensitivity associated with selected genetic and phenotypic features in both CLL and AML specimens. Among AML samples, 11q23 MLL rearrangements were highly sensitive to IBR + VEN. Analysis of differentially expressed genes with respect to IBR + VEN sensitivity indicated pathways preferentially enriched in patient samples with reduced ex vivo sensitivity, including IL-10 signaling. These findings suggest that IBR + VEN may represent an effective therapeutic option for patients with AML.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据